The assessment of HER2 status in breast cancer: the past, the present, and the future

Impact of the 2013 ASCO/CAPHER2Guideline Updates at an Academic Medical Center That Performs PrimaryHER2FISH Testing

(2015) Kristen E. Muller et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The New Equivocal

(2015) Thomas H. Long et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Dual HER2 Gene Protein Assay

(2015) Zaibo Li et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Gene protein detection platform—a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms

(2015) Gustav Stålhammar et al.   Annals of Diagnostic Pathology

2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice

(2015) Ilaria Pennacchia et al.   BREAST

Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HE

(2015) Gillian C Bethune et al.   HISTOPATHOLOGY

The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer

(2015) Louis P. Garrison et al.   VALUE IN HEALTH

HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide

(2015) Marie-Pierre Chenard et al.   VIRCHOWS ARCHIV

HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer

(2014) Hee Jin Lee et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy

(2014) Hyunkeun Song et al.   BMC CANCER

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

(2014) Peter A. Kaufman et al.   CANCER

A novel gene–protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity

(2014) Yasunori Nishida et al.   Gastric Cancer

The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation

(2014) Andrew H S Lee et al.   JOURNAL OF CLINICAL PATHOLOGY

The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing

(2014) Dominique Werner et al.   Journal of Translational Medicine

Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations

(2014) S. Bianchi et al.   PATHOLOGY & ONCOLOGY RESEARCH

Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification

(2014) Zsuzsanna Varga et al.   PLoS One

Delay to Formalin Fixation Effect on HER2 Test in Breast Cancer by Dual-Color Silver-enhanced In Situ Hybridization (Dual-ISH)

(2014) Thaer Khoury et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study

(2013) Zsuzsanna Varga et al.   BMC CANCER

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

(2013) Edith A. Perez et al.   BREAST CANCER RESEARCH AND TREATMENT

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status

(2013) Louis P. Garrison et al.   CANCER

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma

(2013) Cristiana Buzelin Nunes et al.   JOURNAL OF CLINICAL PATHOLOGY

Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis

(2013) Hedyeh Shafi et al.   JOURNAL OF CLINICAL PATHOLOGY

Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31

(2013) Katherine L. Pogue-Geile et al.   JNCI-Journal of the National Cancer Institute

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

(2013) Wedad M Hanna et al.   MODERN PATHOLOGY

HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays

(2013) Lucas Faria Abrahão-Machado   WORLD JOURNAL OF GASTROENTEROLOGY

Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management

(2013) Alexander Valent et al.   Cancer Genetics

Simultaneous Analysis of HER2 Gene and Protein on a Single Slide Facilitates HER2 Testing of Breast and Gastric Carcinomas

(2012) Astrid Hirschmann et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance

(2012) Yi-ling Yang et al.   BREAST CANCER RESEARCH AND TREATMENT

A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

(2012) Hiroaki Nitta et al.   Diagnostic Pathology

Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast

(2012) Andrew H S Lee et al.   HISTOPATHOLOGY

Quantitative Analysis of Diagnostic Guidelines for HER2-Status Assessment

(2012) Albrecht Stenzinger et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues

(2012) V. M. Neumeister et al.   JNCI-Journal of the National Cancer Institute

Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry

(2012) Bryce P Portier et al.   MODERN PATHOLOGY

‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases

(2012) Martin C Chang et al.   MODERN PATHOLOGY

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor and HER2 expression in invasive breast carcinoma

(2012) Isil Z Yildiz-Aktas et al.   MODERN PATHOLOGY

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

(2012) Hyesil Seol et al.   MODERN PATHOLOGY

Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations

(2011) Kimberly H. Allison et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

HeterogeneousHER2Gene Amplification

(2011) Alastair I. Bartlett et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Evaluation of Dual Immunohistochemistry and Chromogenic In Situ Hybridization for HER2 on a Single Section

(2011) Emily S. Reisenbichler et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Genetic heterogeneity in HER2 testing may influence therapy eligibility

(2011) Barbara Bernasconi et al.   BREAST CANCER RESEARCH AND TREATMENT

Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification

(2011) A. H. S. Lee et al.   JOURNAL OF CLINICAL PATHOLOGY

HER2 genetic heterogeneity in breast carcinoma

(2011) C. Ohlschlegel et al.   JOURNAL OF CLINICAL PATHOLOGY

Achieving 95% Cross-Methodological Concordance in HER2 Testing

(2010) Erin E. Grimm et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

(2010) S Guiu et al.   BRITISH JOURNAL OF CANCER

Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer

(2010) Julie M. Wu et al.   HUMAN PATHOLOGY

Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neuAmplification

(2009) Matteo Brunelli et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Delay to formalin fixation effect on breast biomarkers

(2009) Thaer Khoury et al.   MODERN PATHOLOGY

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)

(2008) Hiroaki Nitta et al.   Diagnostic Pathology

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE